# EDGAR Filing Document

**Accession Number:** 0001703647
**File Stem:** 0001193125-23-034390
**Filing Date:** 2023-2
**Character Count:** 26389
**Document Hash:** 721b654af5a96370df4ae0a17dc3600a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-034390.hdr.sgml**: 20230213

**ACCESSION NUMBER**: 0001193125-23-034390

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 31

**CONFORMED PERIOD OF REPORT**: 20230213

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Cost Associated with Exit or Disposal Activities

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230213

**DATE AS OF CHANGE**: 20230213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Frequency Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001703647
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 472324450
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39062
- **FILM NUMBER:** 23614832

**BUSINESS ADDRESS:**
- **STREET 1:** 75 HAYDEN AVENUE
- **STREET 2:** SUITE 300
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421
- **BUSINESS PHONE:** 781-315-4600

**MAIL ADDRESS:**
- **STREET 1:** 75 HAYDEN AVENUE
- **STREET 2:** SUITE 300
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): February 13, 2023

------

## FREQUENCY THERAPEUTICS, INC.

#### (Exact name of Registrant as Specified in Its Charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39062** | **47-2324450** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

#### 75 Hayden Avenue, Suite 300

#### Lexington, MA 02421

#### (Address of principal executive offices) (Zip Code)
(781) 315-4600

#### (Registrant's telephone number, include area code)

#### N/A

#### (Former Name or Former Address, if Changed Since Last Report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common stock, par value $0.001 per share | FREQ | The Nasdaq Stock Market LLC (The Nasdaq Global Select Market) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02.** | **Results of Operations and Financial Condition.**  |

---

On February 13, 2023, Frequency Therapeutics, Inc. (the "Company") announced that, as of December 31, 2022, its cash, cash equivalents and marketable securities were $83.1 million (excluding restricted cash), or $68.9 million net of debt.

The cash, cash equivalents and marketable securities information above is based on preliminary unaudited information and management estimates for the year ended December 31, 2022, is not a comprehensive statement of the Company's financial results as of and for the fiscal year ended December 31, 2022, and is subject to completion of its financial closing procedures. The Company's independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, this preliminary estimate.

The information contained in this Item 2.02 of this Current Report on Form 8-K (the "Current Report") shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing and except as expressly provided by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 2.05.** | **Costs associated with Exit or Disposal Activities**  |

---

Also on February 13, 2023, the Company announced a reduction in force (the "Reduction") of approximately 55% of its workforce. The purpose of the Reduction, which was approved by the Board of Directors of the Company on February 11, 2023, is to better align the Company's workforce with the needs of its business and focus more of its capital resources on its pre-clinical program for remyelination in Multiple Sclerosis (the "MS Program"). These changes will preserve capital, ensuring that the Company is appropriately resourced to complete a first clinical trial of its MS Program.

The Reduction will take place in phases and be completed by April 30, 2023. The total costs related to the Reduction are estimated to be approximately $4 million in future cash outlays primarily related to severance costs and related expenses.

---

| | |
|:---|:---|
| **Item 5.02.** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**  |

---

*Chief Executive Officer Appointment* 

On February 11, 2023, the Company's Board of Directors appointed Christopher Loose, Ph.D., as Interim Chief Executive Officer while David Lucchino, the Company's President and Chief Executive Officer, is on a temporary medical leave of absence after being hospitalized with bacterial meningitis. Mr. Lucchino is expected to make a full recovery. Dr. Loose will also continue to serve as the Company's Chief Scientific Officer. The Company expects Mr. Lucchino will resume his position in full as Chief Executive Officer upon his return.

Dr. Loose, age 42, co-founded the Company and has served as its Chief Scientific Officer since January 2016. Prior to founding the Company, Dr. Loose co-founded Semprus with Mr. Lucchino and Dr. Robert Langer and served as its Chief Technology Officer from June 2007 until its acquisition by Teleflex in June 2012. At Semprus, he led the technology team in the development through regulatory clearance of medical products designed to reduce infection and clotting. Prior to Semprus, Dr. Loose worked as a chemical engineer at Merck Research Labs. In 2011, Dr. Loose was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation. From 2014 to 2021, Dr. Loose served as an Associate Professor Adjunct of Urology at the Yale School of Medicine and Executive Director of Yale University's Center for Biomedical Innovation and Technology, and he continues to serve as a Lecturer in Yale School of Management. Dr. Loose holds a Ph.D. in Chemical Engineering from MIT and a BSE in Chemical Engineering summa cum laude from Princeton University.

------

*Chief Development Officer Departure* 

As part of the Reduction, Carl P. LeBel, Ph.D. will be stepping down as the Company's Chief Development Officer, effective March 31, 2023.

---

| | |
|:---|:---|
| **Item 7.01.** | **Regulation FD Disclosure.**  |

---

On February 13, 2023, the Company posted an updated corporate slide presentation in the "Investors & Media" portion of its website at www.frequencytx.com. A copy of the slide presentation is attached as Exhibit 99.1 to this Current Report.

The information in Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

#### Forward-Looking Statements
This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the timing of the Company's MS Program, Mr. Lucchino's return to his position as chief executive officer, and the sufficiency of the Company's capital resources, including to complete a first clinical trial of the Company's MS Program.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of COVID-19 on the Company's ongoing and planned clinical trials, research and development and manufacturing activities, the Company's business and financial markets; the Company has incurred and will continue to incur significant losses and is not and may never be profitable; the Company's need for additional funding to complete development and commercialization of any product candidate; the unproven approach of the PCA platform and the inability to identify additional potential product candidates; the lengthy, expensive and uncertain process of clinical drug development and regulatory approval; the Company's limited experience successfully obtaining marketing approval for and commercializing product candidates; the results of pre-clinical studies not being indicative of the results from clinical trials; adverse events or undesirable side effects; disruptions at the FDA and other regulatory agencies; failure to identify additional product candidates; new or changed legislation; costly and damaging litigation, including related to product liability or intellectual property or brought by stockholders; misconduct by employees or independent contractors; reliance on third parties, including to conduct clinical trials and manufacture product candidates; compliance with changing laws and regulations, including healthcare and environmental, health, data privacy and safety laws and regulations; failure to obtain, maintain and enforce protection of patents and other intellectual property rights covering product candidates; security breaches or failure to protect private personal information; attracting and retaining key personnel; and the Company's ability to manage growth.

These and other important factors discussed under the caption "Risk factors" in the Company's Form 10-Q filed with the Securities and Exchange Commission ("SEC") on November 8, 2022 and its other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report. Any such forward-looking statements represent management's estimates as of the date of this Current Report. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this Current Report.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.**  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits

The following exhibits relate to Items 7.01, and shall be deemed to be furnished, and not filed:

---

| | |
|:---|:---|
| Exhibit<br>No. | Description |
| 99.1 | [Frequency Therapeutics, Inc. Corporate Slide Presentation as of February 13, 2023](d463460dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | FREQUENCY THERAPEUTICS, INC. | FREQUENCY THERAPEUTICS, INC. |
| Date: February 13, 2023 | By: | /s/ Richard Mitrano |
|  | Name: | Richard Mitrano |
|  | Title: | Vice President of Finance and Operations |

---

## Exhibit 99.1

![Slide 1](g463460ex99_1s1g1.jpg)

Pioneering a New Category in Regenerative Medicine Frequency Therapeutics Corporate Presentation February 2023 Exhibit 99.1

------

![Slide 2](g463460ex99_1s2g1.jpg)

Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including the treatment potential and timing of Frequency Therapeutics' (the "Company") remyelination program in multiple sclerosis ("MS Program"), including the timing of entering the clinic, the ability of our progenitor cell activation ("PCA") platform to provide patient benefit, the potential application of the PCA platform to other diseases, and the sufficiency of the Company's cash and cash equivalents. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of COVID-19 on the Company's planned clinical trials, research and development and manufacturing activities, the Company's business and financial markets; the Company has incurred and will continue to incur significant losses and is not and may never be profitable; need for additional funding to complete development and commercialization of any product candidate; the Company's development and commercialization of any product candidate; the unproven approach of the PCA platform; the lengthy, expensive and uncertain process of clinical drug development and regulatory approval; limited experience successfully obtaining marketing approval for and commercializing product candidates; the results of pre-clinical studies not being indicative of the results from clinical trials; adverse events or undesirable side effects; disruptions at the FDA and other regulatory agencies; failure to identify additional product candidates; new or changed legislation; costly and damaging litigation, including related to product liability, intellectual property or brought by stockholders; misconduct by employees or independent contractors; reliance on third parties, including to conduct clinical trials and manufacture product candidates; compliance with laws and regulations, including healthcare and environmental, health, and safety laws and regulations; failure to obtain, maintain and enforce protection of patents and other intellectual property; security breaches or failure to protect private personal information; attracting and retaining key personnel; and ability to manage growth. These and other important factors discussed under the caption "Risk factors" in the Company's Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 8, 2022 and its other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Any such forward-looking statements represent management's estimates as of the date of this presentation. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation.

------

![Slide 3](g463460ex99_1s3g1.jpg)

Opportunity Advancing a potential first in class remyelination therapeutic for Multiple Sclerosis Potential to transform treatment Plan to enter the clinic in H1 2024 Vision A new approach to regenerative medicine Using small molecules to activate the body's innate regenerative potential Potentially applicable to many degenerative diseases

------

![Slide 4](g463460ex99_1s4g1.jpg)

Company to discontinue hearing programs, continue focus on remyelination and early research FX-322, FX-345 programs for cochlear regeneration discontinued following FX-322-208 readout In 208 study FX-322 was equivalent to placebo Untreated ears did not improve, though improvements were seen in ears injected with placebo Advancing remyelination program to address the top unmet need in multiple sclerosis Novel target and NCEs identified at Frequency Preclinical head-to-head data show new Frequency compounds outperform multiple, well studied comparator compounds Aim to enter the clinic in 1H 2024 Balance sheet sufficient to reach key pipeline inflection points $83.1 mm cash and cash equivalents as of December 31, 2022 Runway into 2025 Reduced headcount and expenses Revised Corporate Strategy Post Phase 2b Hearing Readout

------

![Slide 5](g463460ex99_1s5g1.jpg)

Frequency's Progenitor Cell Activation (PCA) Platform Frequency is developing small molecules that activate endogenous Oligodendrocyte Progenitor Cells to generate new oligodendrocytes and remyelinate the brain Oligodendrocyte Precursor Cell Differentiating Oligodendrocyte Myelin Mature Oligodendrocyte Monje, 2018 Confidential – Do Not Distribute

------

![Slide 6](g463460ex99_1s6g1.jpg)

Novel Frequency Small Molecule Inhibitors Drive Oligodendrocyte Differentiation FREQ-162 Highly potent Highly efficacious Orally bioavailable Brain penetrant Novel chemical entity Patent application filed Lead Optimization generated FREQ-162 % Newly Differentiated Oligodendrocytes Vehicle Negative Control 1 nM 3 nM 10 nM 30 nM 100 nM Frequency discovered a novel and highly effective target Developed novel chemical entities that are highly potent inducers of oligodendrocyte differentiation

------

![Slide 7](g463460ex99_1s7g1.jpg)

Adult mice received 3 doses of comparator compounds or a single dose of FREQ-162 Brains were stained for a marker of newly generated oligodendrocytes Single dose FREQ-162 induces more OPCs to differentiate than comparator compounds FREQ-162 Outperforms Literature Compounds In Vivo Vehicle α-Lingo Antibody Clemastine / Anti-Muscarinic 75 mg/kg x 3 days 5 mg/kg x 3 days T3 / Thyromimetic 10 mg/kg x 3 days x 3 days Thyroid Hormone: Thyromimetic Class α-Lingo antibody: Blocking antibody Clemastine: Anti-Muscarinic Class FREQ-162 5 mg/kg, Single Dose FREQ-162 induces formation of newly differentiated oligodendrocytes in both white and gray matter

------

![Slide 8](g463460ex99_1s8g1.jpg)

Myelin Basic Protein Cortex Striatum Corpus Callosum Cuprizone, Vehicle The Cuprizone Model of Chronic Demyelination Adult mice were demyelinated via 17 months of cuprizone administration Elderly mice with long term demyelination Healthy Control Myelin Basic Protein

------

![Slide 9](g463460ex99_1s9g1.jpg)

Adult mice received up to 10 daily doses of comparators or a single dose of FREQ-162 Brains were stained for Myelin Basic Protein (green) Single dose FREQ-162 induces more remyelination than comparator compounds FREQ-162 Outperforms Published Compounds In Vivo Thyroid Hormone: Thyromimetic Class α-Lingo antibody: Lingo inhibitor Clemastine: Anti-Muscarinic Class FREQ-162 induces formation of new myelin in white and gray matter α-Lingo Antibody Clemastine / Anti-Muscarinic 75 mg/kg x 10 doses 5 mg/kg x 3 doses T3 / Thyromimetic 10 mg/kg x 10 doses FREQ-162 5 mg/kg, Single Dose Vehicle x 10 doses Animals demyelinated for 17 months via cuprizone treatment

------

![Slide 10](g463460ex99_1s10g1.jpg)

Frequency NCEs Outperform Competitors: High Magnification Cortex Striatum Corpus Callosum Vehicle Cortex Striatum Corpus Callosum 5 mg/kg x 1 dose FREQ-162 Myelin Basic Protein High magnification view reveals that FREQ-162 yields myelination In both white and gray matter In the appropriate orientation and location

------

![Slide 11](g463460ex99_1s11g1.jpg)

All 8 out of 8 mice treated with FREQ-162 showed robust increases in myelination in both white and gray matter tracts FREQ-162: Highly Reproducible Increases in Myelination Vehicle FREQ-162 #1 #2 #3 #4 #5 #6 #7 #8 #1 #2 #3 #4 #5 #6 #7 #8 Myelin Basic Protein

------

![Slide 12](g463460ex99_1s12g1.jpg)

Freq-162 Induces Robust Increases in Myelination Forebrain myelin basic protein levels quantitated A single dose of a Frequency compound induces robust remyelination Compound Dose (mg/kg) # of doses Fold change P= α-Lingo antibody 5 3 0.9 x 0.99 Clemastine 75 10 1.7 x 0.70 Thyroid Hormone (T3) 10 10 1.4 x 0.95 FREQ-162 5 1 7.7 x <0.0001 Myelin Basic Protein MBP (Intensity Weighted Pixel Count) 6000 5000 4000 3000 2000 1000 0 Healthy Naive Vehicle Lingo Ab (5 mg/kg) Clemastine (75 mg/kg) T3 (10 mg/kg) FREQ-162 (5 mg/kg)

------

![Slide 13](g463460ex99_1s13g1.jpg)

Discovered novel target Induced high levels of oligodendrocyte differentiation and remyelination in vivo Candidate to enter IND-enabling studies Remyelination: Advancing Toward the Clinic

------

![Slide 14](g463460ex99_1s14g1.jpg)

Appendix

------

![Slide 15](g463460ex99_1s15g1.jpg)

Proven Leadership Team David Lucchino President, CEO & Co-Founder Former CEO of Entrega Bio (PureTech). Co-founder / CEO of Semprus BioSciences (acquired), Polaris Partners. MIT Sloan Fellow. Chris Loose, Ph.D. Chief Scientific Officer & Co-Founder Co-founder/CTO of Semprus BioSciences through FDA / CE clearance and acquisition. Princeton, MIT, Hertz Fellow and Yale Faculty. Carl Lebel, Ph.D. Chief Development Officer Chief Scientific Officer of Otonomy (2009 to 2016). Executive Director, Amgen. Scientific fellow of the American Academy of Otolaryngology. Dana Hilt, M.D. Chief Medical Officer (acting) Neurologist and neuroscientist with two decades in biopharma and CNS drug development. Amgen, Lysosomal, Forum Pharma. Wendy Arnold Chief People Officer HR leader with extensive life science experience including senior leadership roles at Kaleido Biosciences, Moderna, Celgene Avilomics Research, and Inotek Pharmaceuticals Quentin McCubbin, Ph.D. Chief Manufacturing Officer Led pharmaceutical sciences and process chemistry at Takeda / Millennium and headed technical operations Cerevel Therapeutics. Sue Stewart, J.D., LLM Chief Regulatory Officer CRO at numerous biopharma companies including Kaleido Biosciences, Candel Therapeutics, and regulatory leadership roles at Tokai Pharma, Transmolar and Genzyme Corp.

------

![Slide 16](g463460ex99_1s16g1.jpg)

Remyelination Advisory Board Steven Galetta, M.D. Professor of Neurology and Ophthalmology, NYU Grossman School of Medicine Richard Rudick, M.D. Independent Consultant. Former Chief Clinical Research Officer and Vice Chairman for Research and Development in the Neurological Institute, Cleveland Clinic Laura J Balcer, M.D, M.S.C.E. Neurologist and Epidemiologist, NYU School of Medicine Alasdair Coles, Ph.D. Professor of Neuroimmunology, University of Cambridge

------

![Slide 17](g463460ex99_1s17g1.jpg)

PCA Regenerative Medicine Advisory Board Jeff Karp, Ph.D. Associate Professor at Brigham and Women's Hospital, Harvard Medical School John LaMattina, Ph.D. Senior Partner at PureTech Health Robert Langer, SC.D. David H. Koch Institute Professor at the Massachusetts Institute of Technology Sheng Ding, Ph.D. Senior Investigator, Gladstone Institute of Cardiovascular Disease Amy Wagers, Ph.D. Forst Family Professor of Stem Cell and Regenerative Biology, Harvard University James Rothman, Ph.D. Sterling Professor of Cell Biology, Yale University Xiaolei Yin, Ph.D. Instructor in Medicine, Harvard Medical School Ken Anderson, M.D. Dana-Farber Cancer Institute Kraft Family Professor of Medicine, Harvard Medical School Jeffrey Holt, Ph.D. Professor of Otolaryngology and Neurology, Harvard Medical School Sean J. Morrison, Ph.D. Director of the Children's Medical Center Research Institute, UT Southwestern Siddhartha Mukherjee, M.D., D.Phil. Assistant Professor of Medicine, Columbia University Medical Center Steve Haggarty, Ph.D. Associate Professor of Neurology, Harvard Medical School Peter Schultz, Ph.D. Chief Executive Officer of the Scripps Research Institute Ralph Mazitschek, Ph.D. Assistant Professor, Harvard Medical School

------

![Slide 18](g463460ex99_1s18g1.jpg)

Pioneering a New Category in Regenerative Medicine Frequency Therapeutics Corporate Presentation February 2023